Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Vitry
A I
AI
Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Australia. agnes.vitry@unisa.edu.au
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D000077341:Lapatinib; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010506:Periodicals as Topic; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D000068258:Bevacizumab; D017239:Paclitaxel